{"id":1012225,"date":"2026-10-21T16:05:51","date_gmt":"2026-10-21T20:05:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/"},"modified":"2026-10-21T16:05:51","modified_gmt":"2026-10-21T20:05:51","slug":"genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/","title":{"rendered":"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MILAN, Italy, Oct.  21, 2026  (GLOBE NEWSWIRE) &#8212; Genenta Science S.p.A. (Nasdaq: GNTA) (the \u201cCompany\u201d) today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).<\/p>\n<p align=\"justify\">The notification was issued because the closing bid price of the Company\u2019s American Depositary Shares (\u201cADSs\u201d) was below $1.00 per ADS for 30 consecutive business days, from September 3, 2026 through October 15, 2026. The notification does not result in the immediate delisting of the Company\u2019s ADSs, which will continue to trade on the Nasdaq Capital Market under the symbol \u201cGNTA,\u201d subject to the Company\u2019s continued compliance with other applicable listing requirements.<\/p>\n<p align=\"justify\">Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, until April 14, 2027, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company\u2019s ADSs must be at least $1.00 per ADS for a minimum of 10 consecutive business days during the compliance period, unless Nasdaq exercises its discretion to extend this period.<\/p>\n<p align=\"justify\">If the Company does not regain compliance by April 14, 2027, it may be eligible for an additional 180-calendar-day compliance period, provided that it satisfies the applicable market value of publicly held shares requirement and all other initial listing standards for the Nasdaq Capital Market, except the minimum bid price requirement, and provides written notice of its intention to cure the deficiency, including by effecting a reverse stock split, if necessary.<\/p>\n<p align=\"justify\">As previously disclosed, the Company\u2019s shareholders have already approved a reverse stock split within a range of 1-for-10 to 1-for-20, which the Board of Directors is authorized to implement, if deemed appropriate.<\/p>\n<p align=\"justify\">The Company intends to monitor the closing bid price of its ADSs and evaluate available options to regain compliance with Nasdaq\u2019s minimum bid price requirement. Although the Company will use all reasonable efforts, there can be no assurance that it will regain compliance within the initial compliance period, qualify for any additional compliance period, or otherwise remain in compliance with other Nasdaq continued listing requirements.<\/p>\n<p>\n        <strong>About Genenta Science<\/strong>\n      <\/p>\n<p align=\"justify\">Genenta Science (Nasdaq: GNTA) is evolving into a next-generation strategic consolidator focused on privately held specialized companies operating in Italian national security-regulated sectors, with activities spanning cybersecurity, defense, aerospace, and biotechnology\/biosecurity. Genenta holds a 19% equity interest in S\u00f2phia High Tech and has an option to increase its ownership to 51% at a pre-agreed valuation.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements, including statements regarding the Company\u2019s intentions and ability to regain compliance with Nasdaq\u2019s minimum bid price requirement and maintain its Nasdaq listing. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including fluctuations in the market price of the Company\u2019s ADSs and the Company\u2019s ability to satisfy Nasdaq\u2019s continued listing requirements. Additional risks and uncertainties are described in the Company\u2019s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by applicable law.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MTQ5ZDEwZDAtMjNiMC00YzRkLWExNTgtOGNkNTIxNDg4ZjYyLTEyNjg2NTItMjAyNi0xMC0yMS1lbg==\/tiny\/GENENTA-SCIENCE-SPA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Relations\r\n\r\nGenenta Science S.p.A.\r\nTiziana Pollio, Mobile: +39 348 23 15 143\r\nemail: tiziana.pollio@genenta.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Genenta Science S.p.A. (Nasdaq: GNTA) (the \u201cCompany\u201d) today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The notification was issued because the closing bid price of the Company\u2019s American Depositary Shares (\u201cADSs\u201d) was below $1.00 per ADS for 30 consecutive business days, from September 3, 2026 through October 15, 2026. The notification does not result in the immediate delisting of the Company\u2019s ADSs, which will continue to trade on the Nasdaq Capital Market under &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012225","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Genenta Science S.p.A. (Nasdaq: GNTA) (the \u201cCompany\u201d) today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The notification was issued because the closing bid price of the Company\u2019s American Depositary Shares (\u201cADSs\u201d) was below $1.00 per ADS for 30 consecutive business days, from September 3, 2026 through October 15, 2026. The notification does not result in the immediate delisting of the Company\u2019s ADSs, which will continue to trade on the Nasdaq Capital Market under &hellip; Continue reading &quot;Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-21T20:05:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification\",\"datePublished\":\"2026-10-21T20:05:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/\"},\"wordCount\":541,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/\",\"name\":\"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==\",\"datePublished\":\"2026-10-21T20:05:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/","og_locale":"en_US","og_type":"article","og_title":"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification - Market Newsdesk","og_description":"MILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Genenta Science S.p.A. (Nasdaq: GNTA) (the \u201cCompany\u201d) today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The notification was issued because the closing bid price of the Company\u2019s American Depositary Shares (\u201cADSs\u201d) was below $1.00 per ADS for 30 consecutive business days, from September 3, 2026 through October 15, 2026. The notification does not result in the immediate delisting of the Company\u2019s ADSs, which will continue to trade on the Nasdaq Capital Market under &hellip; Continue reading \"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-21T20:05:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification","datePublished":"2026-10-21T20:05:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/"},"wordCount":541,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/","name":"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==","datePublished":"2026-10-21T20:05:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3OTIwMiM0MDI1MzEwNDYjMjI1NzEwMw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-science-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-notification\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012225"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012225\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}